1120 W. Michigan St.
Indianapolis, IN 46202-5111
Dr. Imel’s clinical and research focus is on bone and mineral disorders, especially rare bone disorders, including X-linked hypophosphatemia (XLH), other hypophosphatemic disorders and rare metabolic bone disorders. His unique background includes dual training and certification in both Adult Endocrinology and Pediatric Endocrinology at Indiana University School of Medicine and Riley Hospital for Children. Dr. Imel is also an Affiliate Scientist of the Regenstrief Institute’s Center for Biomedical Informatics, and Core Director for the Musculoskeletal Informatics Methodology Core of the Indiana Center for Musculoskeletal Health-Clinical Research Core, conducting health informatics studies of clinical musculoskeletal outcomes. He conducts clinical and translational research in both rare and common musculoskeletal diseases, including clinical trials in X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal dominant osteopetrosis (ADO2), as well as osteoporosis, and studies of musculoskeletal complications of chronic conditions. Dr. Imel also conducts research in congenital adrenal hyperplasia and musculoskeletal complications of cystic fibrosis.
His clinical practice includes care of adult and pediatric patients with metabolic bone disorders, including a large population of children and adults with XLH. He also sees young adult patients that have transitioned from pediatric to adult care with conditions such as Turner syndrome and classic congenital adrenal hyperplasia.
Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward L, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong H II, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen C, Skrinar A, Martin JS, Portale AA. Burosumab versus continuation of conventional therapy in children with X-linked hypophosphatemia: a randomised, active-controlled, open-label, phase 3 trial. The Lancet, 2019 Jun 15;393(10189):2416-2427, https://doi.org/10.1016/S0140-6736(19)30654-3 (This was also accompanied by a commentary in the issue). PMCID: PMC7179969
Carpenter TO, Whyte MP, Imel EA, AM Boot, Högler W, Linglart A, Padidela R, van’t Hoff W, Mao M, Chen C, Skrinar A, Kakkis E, San Martin J, Portale AA. Burosumab Therapy in Children with X-linked Hypophosphatemia. New England Journal of Medicine, 2018; 378(21):1987-1998. PMID: 29791829
Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, Weber TJ, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen C, Theodore-Oklota C, Mealiffe M, San Martin J, and Carpenter TO. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults with X Linked Hypophosphatemia: Week 24 Primary Analysis. J Bone and Miner Res 2018;33: 1383-1393. PMID 29947083
DeLacey S, Liu Z, Broyles B, El-Azab SA, Guandique CF, James BC and Imel EA. Hyperparathyroidism and Parathyroidectomy in X-linked Hypophosphatemia Patients. Bone 2019 Oct;127:386-392. PMID: 31276850, PMCID: PMC6836672
Imel EA, Liu Z, Coffman M, Acton D, Mehta R, Econs MJ. Oral Iron Therapy Normalizes Fibroblast Growth Factor 23 (FGF23) in Patients with Autosomal Dominant Hypophosphatemic Rickets. J Bone Miner Res, 2020;35(2):231-8. PMID: 31652009
Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, Thomsen LL, Carpenter TO, Weber T, Brandenburg V, Zoller H. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. JAMA. 2020;323(5):432-43.
Imel EA, Liu Z, Acton D, Coffman M, Gebregziabher N, Tong Y, and Econs MJ. Interferon Gamma-1b Does Not Increase Markers of Bone Resorption in Autosomal Dominant Osteopetrosis. Journal of Bone and Mineral Research, 2019 Aug;34(8):1436-1445, PMID: 30889272, PMCID PMC6697186
Titles & Appointments
- Professor of Medicine
- Professor of Pediatrics